|Bid||36.64 x 1200|
|Ask||37.10 x 700|
|Day's range||36.73 - 37.07|
|52-week range||30.90 - 37.37|
|PE ratio (TTM)||22.81|
|Forward dividend & yield||1.36 (3.68%)|
|1y target est||N/A|
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
JNJ stock is currently trading higher than its 50-day moving average of $141.62 and higher than its 200-day moving average of $136.52. Since Johnson & Johnson’s 3Q17 earnings release, JNJ stock has gained ~8.2%. The ongoing restructuring process in its Medical Devices business, new product launches, and its attractive product pipeline are expected by some to further boost investor sentiment and trigger a stock price rise.
Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
The Zacks Analyst Blog Highlights: Pfizer, Chevron, Cisco, Las Vegas Sands and Dominion Resources